CD36 and breast carcinoma: Moreover, recent studies have revealed that the expression of CD36 in tumor cells may correlate with treatment outcomes and prognosis in various tumor types, including esophageal squamous cell carcinoma, lung squamous cell carcinoma, bladder cancer, luminal A breast cancer, and glioblastoma [5,6,7,8], suggesting that this molecule contributes to tumor progression.